Clinical trial
A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512, a Cold Thermoreceptor Modulator, for the Treatment of Dry Eye Disease (COMET-4)
NCT05493111 is registered in ClinicalTrials.gov with Aerie Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512, a Cold Thermoreceptor Modulator, for the Treatment of Dry Eye Disease (COMET-4)
- Lead sponsor
- Aerie Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 1, 2022
- Completion date
- February 28, 2024
- Enrollment
- 275 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.
dry eye disease